GW's success gooses Zynerba Pharma's price; shares up 66% premarket

|About: GW Pharmaceuticals plc (GWPH)|By:, SA News Editor

Thinly traded nano cap Zynerba Pharmaceuticals (NASDAQ:ZYNE) is up 66% premarket on average volume in connection with the bullish action related to GW Pharmaceuticals' (NASDAQ:GWPH) successful Epidiolex (cannabidiol) study results. Zynerba's lead product candidate is Orphan Drug-tagged ZYN002, a synthetic cannabidiol formulated as a gel for transdermal delivery for the treatment of Fragile X syndrome, an inherited disorder characterized by learning disabilities and cognitive impairment.

Previously: Zynerba's cannabidiol gel an Orphan Drug for Fragile X syndrome (Feb. 25)

Previously: GW Pharma's Epidiolex successful in late-stage study in rare form of epilepsy; shares up 127% premarket (March 14)

Subscribe for full text news in your inbox